Informação sobre produto
KML29 is an amide compound that acts as a cannabinoid receptor agonist. It has been shown to be neuroprotective in in vitro experiments with cultured neurons and in vivo studies with rats injected with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) to induce Parkinson's disease. KML29 also inhibits neuronal death induced by the fatty acid, arachidonic acid, and exhibits anti-cancer activity in a mouse model of prostate cancer. KML29 has been shown to have an effective dose at 1 mg/kg for striatal dopamine release and locomotor activity. The drug also binds to the GABAA receptor and shows efficacy against anxiety, depression, and seizures.
Propriedades químicas
Consulta técnica sobre: 3D-FFC42442 KML29
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
